RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team

November 9, 2021 6:00 AM

RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearanceVANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it's clinical advisory team has completed the primary design of the next-phase...

Read more

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

November 8, 2021 8:00 AM

BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, and Servier, a global pharmaceutical group, today announced that the first patient has been dosed in the phase 1/2 study of PRS-344/S095012, a next...

Read more

Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate

November 8, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Oncology Pharma, Inc. (the "Company") is pleased to provide some insight into the progress of its co-development project with NanoSmart Pharmaceuticals, Inc. for the development of a lead cancer drug candidate.The primary goal of the co-development project is for developing an improved formulation of the cancer drug dactinomycin. Dactinomycin, also known as actinomycin D, is an existing...

Read more

Enzolytics, Inc. Announces Program for Creation of Multiple Monoclonal Antibodies for Veterinary Application Utilizing Hybridoma and Phage Display Technology

November 8, 2021 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / November 8, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) has announced a coherent protocol that it is executing to meet the Company's objective of producing monoclonal antibodies for veterinary application utilizing Hybridoma and Phage Display Technologies.The Company's defined protocol includes:Application of computer analysis (Artificial Intelligence - A.I.) to curate (analyze) the amino...

Read more

CORRECTION: Applied UV's Systems Proven to Kill Candida Auris, an Emerging Multi-Drug-Resistant Fungus

November 5, 2021 7:00 AM

The following replaces and corrects the release issued on October 19, 2021:Candida Auris is a pathogenic disease commonly acquired in hospitals or long-term care facilitiesCenters for Disease Control and Prevention ("CDC") has stated that 30-60% of people with C. auris bloodstream infections dieCDC currently considers Candidiasis as one of the most significant infectious diseases in the world today.Currently, there is no vaccine or preventative...

Read more

BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021

November 4, 2021 9:25 AM

BI-1206 restores rituximab activity in relapsed or refractory patientsDemonstrates ORR 50%, DCR 58%, with complete responses lasting beyond 18 and 24 monthsLUND, SE / ACCESSWIRE / November 4, 2021 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces additional positive interim top-line...

Read more

The New Multi Capsule "Medspresso Torro" Gets Unleashed

November 4, 2021 9:00 AM

CAPE TOWN, SA / ACCESSWIRE / November 4, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:Medspresso™ is pleased to announce the launch of the new Medspresso™ Torro Dual Purpose Home Espresso Maker. The new design is unique in that it's one of very few capsule...

Read more

Pressure BioSciences’ BaroFold Platform Unleashes Hidden Growth Engine as Strong Demand for Protein Therapeutics Leverages PBI’s Protein Refolding Technology

November 4, 2021 8:55 AM

Titans and Emerging Leaders of Biopharma Struggling with Protein Misfolding and Aggregation Issues that Threaten Enormous Revenue Potentials Are Turning to PBI's Uniquely Enabling BaroFold SolutionREMINDER: PBI to Participate in the Benzinga Virtual ALL ACCESS Investor Event Today at 11:20 am ET.SOUTH EASTON, MA / ACCESSWIRE / November 4, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and...

Read more

Edesa Biotech Extends COVID-19 Clinical Study to Poland

November 4, 2021 8:00 AM

Expansion to European Union country follows favorable Phase 2 resultsCompany focusing on critically ill hospitalized patientsTORONTO, ON / ACCESSWIRE / November 4, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Polish regulators have approved a clinical trial application for the investigational use of the company's monoclonal antibody...

Read more

Black Bird Biotech Releases Preliminary Findings from 4-Month MiteXstream(TM) Efficacy Testing; Strong Efficacy Results Clear Company for California Clearance Application

November 3, 2021 8:58 AM

FLOWER MOUND, TX / ACCESSWIRE / November 3, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, announced today that its independent testing lab, Botanical Research in Motion, Inc. (BRIM), a British Columbia-based botanical research firm, had released the preliminary findings of its four-month long multi-faceted study of its EPA-registered MiteXstreamTM biopesticide."We found conclusive...

Read more

Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4

November 3, 2021 7:30 AM

DehydraTECH-CBD also being evaluated in three other human clinical studiesPositive studies would support Lexaria's regulatory approval plansKELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces a significant new study to expand its hypertension clinical program and provides updates on three ongoing human clinical...

Read more

Pressure BioSciences to Participate in the Benzinga ALL ACCESS Investor Event

November 2, 2021 9:37 AM

Company Invites Individual and Institutional Investors, as well as Analysts and Advisors, to Attend Its Live, Virtual Guest Appearance on Thursday, November 4, 2021SOUTH EASTON, MA / ACCESSWIRE / November 2, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and services to the worldwide life sciences,...

Read more

Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 2, 2021 7:00 AM

Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDTDosing completed in part 1a of phase 2a study of PRS-060/AZD1402Dosing to begin this quarter in phase 2 study of cinrebafusp alfaReceived regulatory approval from multiple countries for phase 1/2 study of PRS-344/ S095012Presented preclinical data for PRS-220 at ERS; on track for 2022 clinical initiationInitiated second costim bispecific program in Seagen...

Read more

CB Scientific Announces Addition of Brooke Martellaro as Chief Financial Officer

November 2, 2021 6:00 AM

Seasoned finance executive and business leader to add significant incremental competencies to the Company's executive management teamESCONDIDO, CA / ACCESSWIRE / November 2, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") is a provider of remote ECG cardiac monitoring products and services; simple wearable solutions for detecting potentially life-threatening heart arrhythmias in patients with heart-related issues, both...

Read more

Helix BioPharma Corp. Provides Bi-Weekly MCTO Status Update

November 1, 2021 7:00 PM

RICHMOND HILL, ON / ACCESSWIRE / November 1, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management...

Read more

Apollo Endosurgery, Inc. Reports 28% Revenue Growth in Third Quarter Conference Call and Webcast to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET

November 1, 2021 4:01 PM

AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2021 and recent corporate highlights.Third Quarter 2021 Selected Financial ResultsTotal revenue of $16.4 million, an increase of 28% compared to the third quarter of 2020Endoscopic...

Read more

Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation

November 1, 2021 10:20 AM

- Nanoparticle technology shown to be effective in transforming immunologically "cold" tumors to "hot" -- Data presented support durable antitumor activity -NOVATO, CA / ACCESSWIRE / November 1, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases,...

Read more

Apollo Endosurgery Announces Publication of a Multicenter Study of Its X-Tack(R)Endoscopic HeliX Tacking System

November 1, 2021 9:30 AM

Study demonstrates high success rates, ease of use, and economic value in the treatment of GI defectsAUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced the publication of a multi-center study of the X-Tack®System in closing challenging gastrointestinal defects.Removal of gastrointestinal...

Read more

Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol

November 1, 2021 9:00 AM

New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activityKELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has commenced an important new study exploring whether DehydraTECHTM-CBD evidences superior ability to inhibit seizure activity compared to both...

Read more

Medspress(TM) Announces Webinar: The Art, Craft, and Science of Coffee

November 1, 2021 8:00 AM

CAPE TOWN, SA / ACCESSWIRE / November 1, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:Medspresso™ is pleased to announce its live coffee webinar is scheduled for Friday, 12 November 2021 at 15:00 SAST. The webinar will feature a panel of coffee experts with decades'...

Read more